SGPL1-IN-28 is a novel S1P lyase inhibitor with in vitro IC50 of 120 nM, cell IC50 of 230 nM..

SGD-1882 (PBD dimer, Pyrrolobenzodiazepine dimer) is a novel potent DNA-intercalating payload dimer (PBD dimer) payload for antibody-drug conjugates (ADCs)..

SGC-iMLLT is the first small molecule chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with Kd of 129 and 77 nM respectively, IC50 of 0.26 uM (MLLT1).

SG85 is a potent Enterovirus 3C protease inhibitor with EC50 of 180 nM against EV71 and 60 nM against human rhinovirus 14 in a live virus-cell-based assay.

SG3199 is a PBD dimer warhead component of antibody-drug conjugate (ADC) payload tesirine, demonstrates potently cytotoxic against a panel of human solid tumour and haematological cancer cell lines with mean GI50 of 151.5 pM.

SFV785 (SRPIN-785) is a derivative of SRPIN340 that selectively inhibits NTRK1 and MAPKAPK5 kinase, shows anti-viral activity on HCV, DENV and yellow fever viruses.

SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.

SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8.

Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

Setrobuvir (ANA-598) is an experimental drug candidate For the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir. It is currently in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.For the detailed information of Setrobuvir, the solubility of Setrobuvir in water, the solubility of Setrobuvir in DMSO, the solubility of Setrobuvir in PBS buffer, the animal experiment (test) of Setrobuvir, the cell expriment (test) of Setrobuvir, the in vivo, in vitro and clinical trial test of Setrobuvir, the EC50, IC50,and Affinity of Setrobuvir, Please contact DC Chemicals..

Setiptiline(Org-8282) is a serotonin receptor antagonist.

Setiptiline is a serotonin receptor antagonist.

Setafrastat is a small molecule hair growth stimulator.

Sermorelin is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH).

Serdexmethylphenidate is the dextrorotary form of methylphenidate and a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant..

SERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator that activates the Ca2+-dependent ATPase activity of cardiac SR vesicles but not that of skeletal muscle SR vesicles that lack of phospholamban (PLN).

Seratrodast(AA 2414) is a potent and selective thromboxane A2 receptor (TP) antagonist.

Senktide is a potent, selective agonist of neuromedin K3 (NK3) receptor (EC50 =0.5-3 nM), less potently agonizes the NK1 receptor (EC50=35 µM) and is without effect on the NK2 receptor..

Senexin A is a potent and selective inhibitor of CDK8 and its nearest relative, CDK19 with Kd values of 0.83 μM and 0.31 μM for CDK8 and CDK19 ATP site binding, respectively.

SEN1269 is a novel potent Aβ aggregation inhibitor that binds to monomeric Aβ1-42 with Kd of 4.4 uM, protects neuronal cell lines against an Aβ1-42 insult with IC50 of 15 uM.

Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A.

Semapimod (CNI 1493.

Semapimod (CNI 1493.

Selurampanel (BGG 492) is a selective, orally active and competitive AMPA receptor (AMPAR) antagonist with IC50 of 0.19 uM.

Seliforant (SENS-111, SENS111) is a novel potent, selective histamine H4 receptor antagonist..

Selgantolimod is a novel toll-​like receptor TLR8 modulator for the treatment of HIV infection..

Selective reverse transcriptase inhibitor. Exhibits 100-fold selectivity for HIV reverse transcriptase over DNA polymerase α.

Selective AMPA receptor antagonist (Ki values are 84, 2200 and > 37000 nM For AMPA, kainate and NMDA receptors respectively). Neuroprotective.

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.